BMP2 Surrogate Protein with Cleavable Linker for Targeted Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BMP2 protein therapies for osteoarthritis are inefficient due to low recombinant protein activity, leading to high dosages and side effects like inflammation, as they activate monocytes and macrophages, causing pain and bone/cartilage resorption.
Innovation Solution
A BMP2 surrogate protein with two antigen binding regions (ABR) specifically binding to BMPR1a and BMPR2 receptors, joined by a cleavable linker that is selectively cleaved by proteases in monocytes and macrophages, allowing targeted delivery to skeletal stem cells while minimizing activity in these cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high dosage of BMP2 is used to achieve effective cartilage regeneration, then regeneration efficiency is improved, but inflammation and side effects increase
Solution Approach 1:
The patent applies local quality by creating a BMP2 surrogate protein with differential binding affinity - it binds strongly to BMPR1a and BMPR2 receptors in skeletal stem cells at the injury site while having reduced binding to receptors in monocytes and macrophages. This localized specificity allows effective cartilage regeneration at the target site without triggering systemic inflammation and side effects associated with high-dose BMP2 therapy
Solution Approach 2:
The patent changes the binding parameter of the BMP2 surrogate protein by engineering modified amino acid sequences in the antigen-binding regions. These parameter changes enable selective binding to BMPR1a and BMPR2 with high affinity while reducing off-target binding to monocyte and macrophage receptors, thereby achieving effective regeneration at lower dosages with reduced inflammation
2Productivity
If recombinant BMP2 protein is used for therapy, then cartilage regeneration is promoted, but protein activity is low requiring high dosages
Solution Approach 1:
The patent changes the structural parameters of the BMP2 protein by creating a surrogate with modified amino acid sequences in the antigen-binding regions (residues 17-35 and 73-91). These parameter changes enhance the binding affinity and specificity to BMPR1a and BMPR2 receptors, significantly improving protein activity and enabling effective therapy at lower dosages
3Adaptability or versatility
If BMP2 activates monocytes and macrophages, then immune response is enhanced, but pain and bone/cartilage resorption increase
Solution Approach 1:
The BMP2 surrogate protein exhibits local quality through differential receptor binding - it maintains strong interaction with BMPR1a and BMPR2 in skeletal stem cells to promote cartilage regeneration, while its reduced binding affinity to receptors in monocytes and macrophages minimizes unwanted immune activation. This spatially selective binding prevents pain and bone/cartilage resorption caused by excessive immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances BMP2 activity and delivery to skeletal stem cells, reducing side effects and improving cartilage regeneration by promoting chondrogenic differentiation with reduced inflammation.
Implementation Method 1
A first ISV specifically binds to a first BMP2 receptor, e.g. BMPR1a; and a second ISV specifically binds to a second BMP2 receptor, e.g. BMPR2
Implementation Method 2
the first and second ISV are joined by a cleavable linker that is susceptible to proteases selectively expressed in monocytic cells or macrophages, relative to skeletal stem cells
Data Source
AI summary
A BMP2 surrogate protein is provided comprising two different antigen binding regions (ABR), which can be configured as immunoglobulin “single variable domains” (ISV). A first ISV specifically binds to a first BMP2 receptor, e.g. BMPR1a; and a second ISV specifically binds to a second BMP2 receptor, e.g. BMPR2. In some embodiments the first and second ISV are joined by a cleavable linker that is susceptible to proteases selectively expressed in monocytic cells or macrophages, relative to skeletal stem cells.